Research article summary (published 4 Aug 2009):

Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients?

Full Abstract

AIM: Factor V Leiden (R506Q) mutation is the most commonly observed inherited genetic abnormality related to vein thrombosis. Lebanon has one of the highest frequencies of this mutation in the world with a prevalence of 14.4% in the general population. The aim of this study is to define risk factors including inherited genetic abnormalities among Lebanese patients with lower extremity deep vein thrombosis. We report the clinical outcome of patients with thrombophilia. METHODS: From January 1998 to January 2008, 162 patients (61 males and 101 females) were diagnosed with lower extremity deep vein thrombosis. Mean age was 61 years (range: 21 to 95 years). RESULTS: The most frequent risk factors for vein thrombosis were surgery, advanced age, obesity, and cancer. Twenty-five patients had thrombophilia, 16 patients had factor V Leiden (R506Q) mutation, and seven patients had MTHFR C677T mutation. Ninety-two percent of patients screened for thrombophilia were positive. Screening was requested in young patients (16), patients with recurrent (11), spontaneous (8), and extensive (5) venous thrombosis, familial history (5), pregnancy (4), estroprogestative treatment (3), and air travel (1). Nine patients had one, 11 patients had two, and five had three of these conditions. Follow-up (6 to 120 months) of these 25 patients treated with antivitamin K did not reveal recurrences or complications related to venous thromboembolism. CONCLUSION: Factor V Leiden mutation followed by MTHFR mutation are the most commonly observed genetic abnormalities in these series. Defining risk factors and screening for thrombophilia when indicated reduce recurrence rate and complications. Recommendations for thrombophilia screening will be proposed.

Author information

Author/s: Kreidy, R (R); Irani-Hakime, N (N);

Affiliation: Department of Vascular Surgery, Saint George Hospital, University Medical Center, Youssef Sursock Street, PO Box 166378, Achrafieh, Beirut 11002807, Lebanon. docrkdy(-atsign-)inco.com.lb

Journal and publication information

Publication Type: Journal Article

Journal: Vascular health and risk management (Vasc Health Risk Manag), published in New Zealand. (Language: eng)

Reference: 2009-; vol 5 (issue ) : pp 627-33

Dates: Created 2009/08/18; Completed 2009/10/29;

PMID: 19688103, status: MEDLINE (last retrieval date: 10/29/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult Age Factors Aged Aged, 80 and over Anticoagulants - therapeutic use Asian Continental Ancestry Group - genetics Factor V - genetics Female Gene Frequency Genetic Predisposition to Disease Humans Incidence Lebanon Lower Extremity - blood supply Male

Mass Screening - methods Methylenetetrahydrofolate Reductase (NADPH2) - genetics Middle Aged Mutation Neoplasms - complications Obesity - complications Recurrence Risk Assessment Risk Factors Surgical Procedures, Operative - adverse effects Thrombophilia - complications; diagnosis; drug therapy; ethnology; genetics Treatment Outcome Venous Thrombosis - drug therapy; ethnology; etiology; genetics Vitamin K - antagonists & inhibitors Young Adult

Associated Chemicals: Anticoagulants (0) ; factor V Leiden (0) ; Vitamin K (12001-79-5) ; Factor V (9001-24-5) ; Methylenetetrahydrofolate Reductase (NADPH2) (EC 1.5.1.20)

Related articles

These are the highest related articles currently in the database:

• Role of thrombophilia in deciding on the duration of anticoagulation. 29 Nov 2004
• Genetic thrombophilia in patients with VTE in eastern Mediterranean located tertiary care center; is it time to change the algorithm for thrombophilia work up decision making? 30 May 2006
• [Genetic determinants of hereditary thrombophilia in pathogenesis of venous thrombosis] 30 Dec 2002
• Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences. 19 Dec 2007
• Prevalence of Factor V Leiden in three ethnic groups of patients with deep vein thrombosis in the Western Cape province of South Africa. 29 Jun 2000
• The prevalence of C677T mutation in the methylenetetrahydrofolate reductase gene and its association with venous thrombophilia in Taiwanese Chinese. 30 Jan 2000
• Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis. 13 Feb 2001
• Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis. 12 Apr 2004
• Diagnosis and treatment of deep vein thrombosis. 30 Aug 2000
• Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. 30 Mar 2008

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.